Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Chemotherapy effectiveness is limited by poor drug selectivity and tumor microenvironment barriers.
• Heterogeneous tumor perfusion, vascular permeability, and interstitial pressure impede drug penetration.
• Developing strategies to enhance drug delivery to neoplastic cells is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To investigate tumor vascular targeting strategies for improving chemotherapeutic drug concentration and therapeutic index.
• To evaluate the efficacy of TNF-alpha and liposome-based drug delivery systems targeting tumor neovasculature.
• To overcome barriers limiting drug penetration into tumor cells distant from blood vessels.

Main Methods:

• Vascular targeting using tumor necrosis factor alpha (TNF-alpha) coupled with a cyclic CNGRC peptide (CD13 ligand).
• Encapsulation of doxorubicin into liposomes targeted to tumor vessels via a linear GNGRG peptide.
• Assessment of drug penetration and therapeutic index in mouse models of subcutaneous and orthotopic neuroblastoma xenografts.

Main Results:

• NGR-TNF-alpha treatment altered tumor barriers, increasing chemotherapeutic drug penetration in subcutaneous tumors.
• Liposomal doxorubicin targeted with GNGRG peptide showed improved drug uptake and therapeutic index in neuroblastoma tumors.
• Both indirect (NGR-TNF-alpha) and direct (NGR-targeted liposomes) vascular targeting enhanced drug delivery and efficacy.

Conclusions:

• Tumor vascular targeting offers a novel approach to increase the therapeutic index of chemotherapeutic drugs.
• Targeted delivery of therapeutic agents can overcome limitations associated with conventional chemotherapy.
• These strategies hold promise for improving the effectiveness of cancer treatment by enhancing drug delivery to tumors.